78 results about "Squamous Cell Cancers" patented technology

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

The application discloses a photosensitizer conjugate for targeted treatment of tongue squamous cell carcinoma and a preparation method and application thereof, and belongs to the technical field of biological medicines. A novel PROTAC-PDT conjugate Gef-PRO-SS-TPE is synthesized, and the compound connects a PROTAC molecule Gef-PRO targeting EGFR and an AIE photosensitizer TPE derivative through a breakable disulfide bond. On one hand, Gef-PRO can specifically degrade EGFR and block tumor cell proliferation signals; on the other hand, the TPE derivative can generate ROS under light conditions and induce cell apoptosis. More importantly, the disulfide bond can be broken in response to high concentrations of glutathione (GSH) in tumor cells, realizing controllable release of Gef-PRO and TPE molecules, so as to exert a synergistic anti-tumor effect.

To provide anti-New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen-binding proteins and methods of using the same.SOLUTION: The present disclosure provides antigen-binding proteins that specifically bind to an HLA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5, or more amino acids.SELECTED DRAWING: None

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

The present disclosure relates to detecting one or more types of oropharyngeal cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of oropharyngeal cancer (e.g., HPV+ oropharyngeal squamous cell cancer) in a biological sample from a subject having or suspected of having an oropharyngeal cancer.

The present disclosure provides antigen-binding proteins that specifically bind to an H LA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5 or more amino acids.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The invention relates to a methylation site marker for assisting in early diagnosis of esophageal squamous cell carcinoma and application of the methylation site marker, and belongs to the technical field of biomedicine. The methylation site marker is one or a combination of human peripheral blood mononuclear cell methylation sites cg05064044, cg03395511 and cg21548813, and the nucleotide sequence of the methylation site marker is as shown in SEQ ID NO. 1-3. According to the present invention, the methylation chip detection results show that the methylation levels of the cg05064044, the cg03395511 and the cg21548813 in the peripheral blood mononuclear cells of the esophageal squamous cell carcinoma patient are significantly increased compared to the health control group; the methylation levels of cg05064044, cg03395511 and cg21548813 sites in PBMC of esophageal squamous cell carcinoma patients in a training queue and a verification queue are all obviously higher than those of a healthy control group through further analysis. Finally, through ROC curve analysis, it is determined that the three methylation sites cg05064044, cg03395511 and cg21548813 have good specificity and sensitivity, have high diagnosis efficiency when being independently or jointly used for esophageal squamous cell carcinoma diagnosis and can be used as potential molecular markers for esophageal squamous cell carcinoma diagnosis.

The invention relates to a computer-implemented method for detecting oesophageal squamous cell dysplasia (OSCD) or oesophageal squamous cell cancer (OSCC) in a cell sample from a subject. This invention also relates to a computer-implemented method for generating a trained model to detect OSCD or OSCC. This invention also relates to a computer-readable storage medium or a computer program comprising instructions which when executed by a computer, are capable of causing the computer to perform the method. This invention also relates to a kit comprising the computer program or computer-readable storage medium and a non-endoscopic cell collection device. The invention also relates to an apparatus for performing the method. The invention further relates to the use of genome wide instability scores (GWIS) as a diagnostic marker for cancer, wherein GWIS is a measure of the CNV across a plurality of autosomal arms in a cell sample from a subject.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The invention belongs to the technical field of medicines, and particularly discloses an oral squamous cell carcinoma inhibitor and application thereof. The inhibitor takes rutin as an active component. In-vitro experiments prove that rutin can significantly inhibit proliferation, clone formation, migration and invasion ability of OSCC cells in a dose-dependent manner, and effectively induce cell apoptosis. The action mechanism of the rutin is as follows: the rutin can directly target STAT3 protein and inhibit phosphorylation of the STAT3 protein so as to regulate and control a downstream BCL2 / CASP3 apoptosis pathway, thereby playing a role in treating OSCC. Molecular docking results further show that rutin and STAT3 have strong binding capacity. The invention discloses a new application of rutin as an STAT3 inhibitor in treating oral squamous cell carcinoma, and provides a new strategy and a candidate compound for developing high-efficiency and low-toxicity OSCC treatment medicines.

This invention discloses a method and system for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma, belonging to the field of two-dimensional image processing technology for oral squamous cell carcinoma. It aims to improve the accuracy and stability of early screening for oral squamous cell carcinoma. The invention acquires oral image data, labels the acquired images according to pre-set classification standards to obtain training and testing sets; preprocesses the oral image data to obtain preprocessed training and testing sets; performs data augmentation on the oral image data in the training set to obtain a data-augmented training set; constructs an image feature extraction model based on a convolutional neural network; and trains the convolutional neural network-based image feature extraction model using supervised learning to obtain a trained convolutional neural network-based image feature extraction model for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma.

The present application relates to the technical field of squamous cell carcinoma early diagnosis, and provides a method for assisting early diagnosis of head and neck squamous cell carcinoma, comprising: S1: collecting existing video data obtained by using MET targeted near-infrared fluorescence imaging technology, and training a supervised learning model by using the video data set; S2: building a classifier system, inputting video data to be classified into the classifier system, and applying the trained supervised learning model to segment and determine the pathological properties of the lesion; S3: comparing the efficiency of the built classifier system and human doctors in diagnosing early head and neck squamous cell carcinoma; S4: screening key features related to the occurrence and development of head and neck squamous cell carcinoma through the classifier system, forming a comprehensive data set by connecting the key features with multi-omics data, building an intermediate model based on the comprehensive data set, and performing bioinformatics analysis by using the intermediate model. The present application can improve the early detection rate of HNSCC, improve the accuracy of biopsy, and realize early and accurate tumor diagnosis.

There is provided the combination of Bacillus Calmette-Guérin (BCG) vaccine and β-glucan adjuvant for the treatment of a cancer characterized by the presence of protumoral T3 neutrophils in the tumour microenvironment. The β-glucan is characterized by a μ-1,3 glucose backbone. The BCG and β-glucan combination demonstrated a synergistic effect in remodeling the tumour microenvironment to resist conversion of neutrophils into the T3 phenotype. The cancer can be bladder cancer, melanoma, lung adenocarcinoma, head and neck squamous cell cancer, pancreatic adenocarcinoma, low-grade gliomas, esophageal carcinoma, and cervical squamous cell carcinoma.

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The application relates to application of FLVCR2-AS1 as a biomarker and therapeutic target of oral squamous cell carcinoma, and belongs to the technical field of biological medicine. The application provides application of FLVCR2-AS1 as a biomarker in preparation of a product for diagnosing oral squamous cell carcinoma, wherein the nucleotide sequence of the FLVCR2-AS1 is shown in SEQ ID NO:1. It is found and identified in the application that FLVCR2-AS1 is specifically lowly expressed in oral squamous cell carcinoma tissues and cell lines, and the expression level is significantly related to the prognosis of patients. Further research finds that overexpression of FLVCR2-AS1 can effectively inhibit the migration and invasion ability of oral squamous cell carcinoma cells. These results prove that FLVCR2-AS1 is a novel molecular target with clinical application potential for oral squamous cell carcinoma.

This invention provides the use of CX6258 or its salts in medicaments for the prevention and / or treatment of lung cancer, belonging to the field of biomedicine. This invention is the first to discover that CX6258HCl can effectively inhibit the growth of lung squamous cell carcinoma cell lines and organoids, and that CX6258HCl can also be combined with cisplatin to treat lung squamous cell carcinoma. Therefore, CX6258 or its salts have broad application prospects in medicaments for the prevention and / or treatment of lung cancer, especially lung squamous cell carcinoma.

The invention relates to the technical field of chemical medicines. The invention provides application of butenol in preparation of a medicine for treating skin squamous cell carcinoma. The invention also provides a butein-containing medicine for treating skin squamous cell carcinoma. According to the invention, butein can inhibit the growth of cSCC cells and reduce the migration ability of the cSCC cells; meanwhile, the protein expression levels of key proteins TWEAK, Fn14 and cIAP1 in tumors can be inhibited.

The invention provides application of an EGFR (epidermal growth factor receptor) inhibitor in preparation of a medicine for treating diseases mediated by the activity of a guanylate exchange factor (GEF) or jointly mediated by the activity of the guanylate exchange factor (GEF) and the activity of EGFR tyrosine kinase. The diseases are cancers selected from the following groups: lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, melanoma, leukemia and glioblastoma. Specifically, the invention discovers that EGFR has a GEF function for promoting activation of Ras homologous protein (Rhb) besides traditional tyrosine kinase activity, the function does not depend on the tyrosine kinase activity and plays a key role by depending on a glutamic acid residue at the 804th site on an EGFR molecule, the Rhb-GEF activity of EGFR causes allosteric activation of a mammal rapamycin target protein complex 1 (mTORC1), and the activity of the EGFR causes allosteric activation of the mammal rapamycin target protein complex 1 (mTORC1). The tumor growth is finally promoted.

The invention provides application of a reagent for detecting the expression quantity of an lncRNA marker in preparation of an oral squamous cell carcinoma diagnosis product or a prognosis product, and relates to the technical field of biological medicines. The lncRNA is DPY19L1P1, and the nucleotide sequence of the lncRNA is as shown in SEQ ID NO. 1. The DPY19L1P1 can be used as a tumor molecular marker to design and synthesize a specific detection reagent or kit, is used for early auxiliary diagnosis of clinical oral squamous cell carcinoma, and improves the diagnosis efficiency and prognosis efficiency of oral squamous cell carcinoma. The invention further provides an application of the reagent for detecting the expression quantity of the lncRNA-DPY19L1P1 in a sample as well as a primer and a kit for specifically detecting the lncRNA-DPY19L1P1. The primer can specifically recognize the DPY19L1P1 and detect the expression quantity of the DPY19L1P1 in a tissue.

The present invention is inter alia directed to a combination comprising at least one nucleic acid molecule that encodes a combination of antigens that comprise an amino acid sequence encoded by ZC3H8-6:1, WDR72-2:4, KCNMB2-AS1:4, and NTF3-5:5. The combination of antigens optionally comprises at least one additional antigen that comprises an amino acid sequence from MAGEA3, MAGEA4, MAGEA11, and / or MAGEA9. The invention further relates to a composition comprising at least one nucleic acid molecule suitably formulated in lipid-based earners. The invention also provides a peptide or protein antigen combination, as well as a kit or kit of parts comprising the combination, the composition, and / or the peptide or protein antigen combination. Also provided herein is the combination, the composition, the peptide or protein antigen combination, or the kit or kit of parts, for use as a medicament, preferably for use in the treatment or prevention of a tumour or cancer disease, more preferably for use in the treatment or prevention of squamous cell carcinoma such as squamous non-small-cell lung cancer or head and neck squamous cell carcinoma.

Nanoparticle-Based Salivary Biosensor for Early Detection of Oral Squamous Cell Carcinoma

The present application relates to the application of sheep oil in the preparation of anti-esophageal cancer cell function supplements, and the sheep oil is used as a nutritional supplement to reduce the esophageal cancer cell activity, maintain the body weight of the esophageal cancer patient, stabilize the nutrition and metabolism index, reduce the inhibition of radiotherapy on the hematopoietic system, improve the immune function of the esophageal cancer patient, reduce the inflammation reaction related to radiotherapy and protect the life quality of the esophageal cancer patient.The present application first proves the positive role of the sheep oil as a nutritional supplement in the treatment of esophageal squamous cell carcinoma patients, especially for the locally advanced unresectable esophageal squamous cell carcinoma patients, and provides a function supplement with lower cost and better effect for the future treatment of esophageal squamous cell carcinoma patients, which has important significance.

The invention relates to the technical field of biological medicine, in particular to application of bufalin serving as an LINC01410 inhibitor to preparation of medicine for inhibiting growth and / or proliferation of esophageal squamous cell carcinoma. The invention provides application of bufalin in preparation of a medicine for preventing and / or treating esophageal squamous cell carcinoma. The invention also finds that bufalin can be used as an inhibitor of LINC01410 for the first time, and proliferation and migration invasion of esophageal squamous cell carcinoma are effectively inhibited by inhibiting expression of LINC01410. The invention provides a new therapeutic target and a potential therapeutic drug for the treatment of esophageal squamous cell carcinoma, and has important clinical application value.

The present invention pertains to a pharmaceutical composition for preventing or treating squamous cell carcinoma, the pharmaceutical composition containing a highly expressed lncRNAs in esophageal squamous cell carcinoma (HERES) expression inhibitor. More specifically, the present invention pertains to a pharmaceutical composition which uses a HERES expression inhibitor to reduce the expression of HERES and affect Wnt signaling pathways, and thereby prevent or treat squamous cell carcinoma.The present inventors discovered that the expression pattern of HERES is related to the onset of squamous cell carcinoma, and found that HERES can be a target for treating squamous cell carcinoma. Accordingly, the pharmaceutical composition according to the present invention was determined to have the effect of inhibiting the proliferation, metastasis, and the like of squamous cell carcinoma by containing the HERES expression inhibitor, and is thus expected to be advantageously used for preventing and treating or ameliorating squamous cell carcinoma.

This invention provides a novel magnifying endoscopic grading method and system for superficial esophageal squamous cell carcinoma based on IPCL recognition, relating to the fields of medical image processing and endoscopic-assisted diagnosis. This invention acquires narrowband or blue light imaging frames, uses a transparent cap for scale calibration, performs vascular enhancement, threshold segmentation, and morphological opening and closing operations on the images, extracts the vascular skeleton and calculates roughness indices, and simultaneously performs connected component analysis and maximum diameter measurement on avascular and stretched regions. Grading is determined by combining preset thresholds across multiple image frames, outputting the grading results and recording key parameters, thus achieving objective, accurate, stable, and repeatable automatic grading of invasion depth.

The application discloses application of circular RNA Hsa_circ_0006332 in diagnosis and treatment of esophageal squamous cell carcinoma and belongs to the field of biological medicine. The application comprises application of a reagent capable of detecting Hsa_circ_0006332 or an expression amount thereof in preparation of a kit for diagnosing esophageal squamous cell carcinoma, wherein the Hsa_circ_0006332 nucleotide sequence is SEQ ID NO. 1. The application also comprises application of a component capable of inhibiting or blocking expression of Hsa_circ_0006332 in preparation of a medicine for treating esophageal squamous cell carcinoma. The application changes an expression level of Hsa_circ_0006332 in esophageal squamous cell carcinoma cells through construction of Hsa_circ_0006332 specific siRNAs and other molecular biology means, reveals that interference with Hsa_circ_000632 expression can significantly inhibit esophageal squamous cell carcinoma cell proliferation, invasion and migration, promote cancer cell apoptosis and other tumor cell biological phenotypes. Therefore, Hsa_circ_0006332 can be used as a treatment target in preparation, screening or treatment of esophageal squamous cell carcinoma or medicines for inhibiting migration and invasion of esophageal squamous cell carcinoma, and provides a new treatment method for intervention or treatment of esophageal squamous cell carcinoma.